Susquehanna International Group, LLP Intra Cellular Therapies, Inc. Call Options Transaction History

Susquehanna International Group, LLP

$527 Billion
Q2 2024

Call Options

28 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 15, 2024	SELL	$64.76 - $79.84 $3.06 Million - $3.77 Million	-47,200 Reduced 37.76%	77,800 $5.33 Million
Q1 2024 May 07, 2024	BUY	$64.37 - $75.65 $276,791 - $325,295	4,300 Added 3.56%	125,000 $8.65 Million
Q4 2023 Feb 14, 2024	BUY	$46.37 - $73.65 $3.12 Million - $4.96 Million	67,300 Added 126.03%	120,700 $8.64 Million
Q3 2023 Nov 14, 2023	SELL	$52.09 - $64.1 $2.55 Million - $3.14 Million	-49,000 Reduced 47.85%	53,400 $2.78 Million
Q2 2023 Aug 11, 2023	SELL	$54.67 - $66.44 $1.51 Million - $1.83 Million	-27,600 Reduced 21.23%	102,400 $6.48 Million
Q1 2023 May 16, 2023	SELL	$43.8 - $56.99 $604,440 - $786,462	-13,800 Reduced 9.6%	130,000 $7.04 Million
Q4 2022 Feb 14, 2023	BUY	$44.07 - $54.45 $484,770 - $598,950	11,000 Added 8.28%	143,800 $7.61 Million
Q3 2022 Nov 14, 2022	BUY	$42.7 - $59.99 $102,480 - $143,976	2,400 Added 1.84%	132,800 $6.18 Million
Q2 2022 Aug 15, 2022	SELL	$43.0 - $65.64 $1.75 Million - $2.68 Million	-40,800 Reduced 23.83%	130,400 $7.44 Million
Q1 2022 May 16, 2022	SELL	$38.74 - $62.09 $3.44 Million - $5.51 Million	-88,800 Reduced 34.15%	171,200 $10.5 Million
Q4 2021 Feb 14, 2022	BUY	$35.2 - $53.42 $1.42 Million - $2.15 Million	40,200 Added 18.29%	260,000 $13.6 Million
Q3 2021 Nov 15, 2021	BUY	$28.72 - $42.49 $2.28 Million - $3.37 Million	79,400 Added 56.55%	219,800 $8.19 Million
Q2 2021 Aug 11, 2021	SELL	$29.3 - $44.5 $1.96 Million - $2.98 Million	-66,900 Reduced 32.27%	140,400 $5.73 Million
Q1 2021 May 17, 2021	SELL	$30.8 - $39.51 $2.8 Million - $3.59 Million	-90,800 Reduced 30.46%	207,300 $7.03 Million
Q4 2020 Feb 16, 2021	SELL	$23.34 - $32.22 $8.02 Million - $11.1 Million	-343,600 Reduced 53.55%	298,100 $9.48 Million
Q3 2020 Nov 16, 2020	BUY	$17.61 - $31.86 $4.92 Million - $8.9 Million	279,500 Added 77.17%	641,700 $16.5 Million
Q2 2020 Aug 14, 2020	BUY	$14.35 - $26.64 $948,535 - $1.76 Million	66,100 Added 22.32%	362,200 $9.3 Million
Q1 2020 May 15, 2020	SELL	$12.31 - $33.12 $10.7 Million - $28.7 Million	-867,700 Reduced 74.56%	296,100 $4.55 Million
Q4 2019 Feb 14, 2020	BUY	$7.26 - $38.49 $6.61 Million - $35.1 Million	910,700 Added 359.82%	1,163,800 $39.9 Million
Q3 2019 Nov 14, 2019	SELL	$7.47 - $14.03 $5.23 Million - $9.83 Million	-700,800 Reduced 73.47%	253,100 $1.89 Million
Q2 2019 Aug 14, 2019	BUY	$10.65 - $14.29 $4.35 Million - $5.83 Million	408,200 Added 74.8%	953,900 $12.4 Million
Q1 2019 May 15, 2019	SELL	$10.9 - $14.09 $2.32 Million - $2.99 Million	-212,400 Reduced 28.02%	545,700 $6.65 Million
Q4 2018 Feb 14, 2019	BUY	$10.36 - $20.96 $3.5 Million - $7.08 Million	337,700 Added 80.33%	758,100 $8.64 Million
Q3 2018 Nov 14, 2018	BUY	$17.77 - $22.9 $1.72 Million - $2.22 Million	96,900 Added 29.95%	420,400 $9.12 Million
Q2 2018 Aug 14, 2018	BUY	$17.33 - $23.4 $3.34 Million - $4.5 Million	192,500 Added 146.95%	323,500 $5.72 Million
Q1 2018 May 15, 2018	BUY	$15.16 - $25.49 $1.58 Million - $2.65 Million	103,900 Added 383.39%	131,000 $2.76 Million
Q4 2017 Feb 14, 2018	SELL	$14.27 - $16.79 $235,455 - $277,035	-16,500 Reduced 37.84%	27,100 $392,000
Q3 2017 Nov 14, 2017	BUY	$10.77 - $22.1 $469,572 - $963,560	43,600	43,600 $688,000

Others Institutions Holding ITCI

# of Institutions

400

Shares Held

87.2M

Call Options Held

309K

Put Options Held

302K

Vanguard Group Inc Valley Forge, PA

9.61M
Shares

$698 Million
0.01% of portfolio
Black Rock Inc. New York, NY

6.32M
Shares

$459 Million
0.01% of portfolio
Wasatch Advisors Inc Salt Lake City, UT

3.72M
Shares

$270 Million
1.37% of portfolio
Jpmorgan Chase & CO New York, NY

3.44M
Shares

$250 Million
0.02% of portfolio
Avoro Capital Advisors LLC New York, NY

3M
Shares

$218 Million
2.8% of portfolio

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $6.86B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account